MindMed Archives

Psychedelics News

MindMed

Press Releases

25 Nov 2020

MindMed Upsizes Previously Announced Bought Deal Public Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES NEW YORKNov....

By Microdose

Press Releases

25 Nov 2020

MindMed Announces $25 Million Bought Deal Public Offering

By Microdose

Press Releases

16 Nov 2020

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety Disorders NEW YORKBASEL, SwitzerlandNov....

By Microdose

Press Releases

30 Oct 2020

MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines

Post-Financing Cash Reserves of CAD $50....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

16 Oct 2020

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Oct....

By Microdose

Press Releases

8 Oct 2020

MindMed Announces $25 Million Bought Deal Public Offering

NEW YORK, Oct....

By Microdose

Press Releases

4 Oct 2020

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

NEW YORK, Oct....

By Microdose

Press Releases

23 Sep 2020

MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

BASEL, Switzerland, Sept....

By Microdose

Press Releases

20 Sep 2020

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

NEW YORK, Sept....

By Microdose

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result